September 23, 2024 7:13am
The news cycle could be light before earnings season ramp up in October
Always have an eye to exit; if the Nasdaq falls back toward the 50-day line and growth falters, dragged down by economic releases … listen to the market
Pre-open Indications: 2 Sell into Strength, 2 Negative and 6 Positive Indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Monday: The pre-open Dow futures are UP +0.096% or (+24 points), the S&P futures are UP +0.16% or (+9 points) and the Nasdaq futures are UP +0.26% or (+52 points)
- Stock futures rose slightly Monday, September 23, 2024
- European stocks were flat in early trading,
- Asia-Pacific markets mostly rose
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Friday: The Dow closed UP +38.17 points or +0.09%, the S&P closed DOWN -11.09 points or -0.19% while the Nasdaq closed DOWN -65.66 points or -0.36%
- Friday’s advance/decline line ended with a negative close at the close of 8 incliner, 24 decliners and 3 flats
Economic Data Docket: S&P Global US Services PMI, September (48.5 expected, 47.9 previously); Chicago Fed Nat Activity Index, August (-.20 expected, -0.34 previously)
- In the week: A Q2 GDP reading due Thursday will help test that contention. Friday's scheduled release of the Personal Consumption Expenditures (PCE) index,
Friday’s RegMed Investors (RMi) Closing bell: “triple witching Friday. As I asked yesterday, “The day after; is there a walk of shame i.e. decline coming as equities moved skyward after rate cut?” Portfolios walked it” …` https://www.regmedinvestors.com/articles/13625
Q3/24:
- September – 7 positive and 8 negative close
- August – I neutral, 10 positive and 11 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength:
Friday, Thursday, Wednesday, Tuesday and last Monday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Blueprint Medicine (BPMC) closed up +$0.74 after Thursday’s +$1.61 after Wednesday’s +$2.82 after Tuesday’s +$0.47 after Monday’s -$2.60 with a zero Friday aftermarket.
Mesoblast (MESO) closed up +$0.44 with a zero after Friday aftermarket.
Negative Indications:
Editas Medicine (EDIT) closed down -$0.14 with a negative -$0.04 or -1.045 Friday aftermarket.
Verve Therapeutics (VERV) closed down -$0.19 with a negative -$0.05 or -0.96% Friday aftermarket.
Positive Indications:
Friday, Thursday, Wednesday, Tuesday and last Monday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Agenus (AGEN) closed down -$0.15 with a positive +$0.26 or +4.45% Friday aftermarket
AxoGen (AXGN) closed down -$0.59 with a positive +$0.01 or +0.07% Friday aftermarket
CRISPR Therapeutics (CRSP) closed down -$1.31 after Thursday’s +$0.10, Wednesday’s +$0.28, Tuesday’s +$1.67 and Monday’s -$1.20 with a positive +$0.17 or +0.35% Friday aftermarket
Intellia Therapeutics (NTLA) closed down - $1.05 with a positive +$0.06 or +0.27% Friday aftermarket
Sage Therapeutics (SAGE) closed down -$0.40 with a positive +$0.16 or +2.13% Friday aftermarket
The BOTTOM LINE: More weakness could lie ahead with more wild swings like those seen over the past 2 months.
Moving forward through September, October and a few weeks of November, I believe the cell and gene therapy sector equities could be a bit rocky as Q3 LPS (loss-per-share) earnings releases step to bat.
- “Elevated prices for futures contracts tied to the Cboe Volatility Index VIX, better known as the VIX or “fear gauge,” suggest traders are bracing for such a risk.” <Matt Thompson, co-portfolio manager at Little Harbor Advisors.>
Keep a close eye on incoming economic data exposure as any sign of increased inflation is likely be a concern for investors.
The Fed’s jumbo 50-basis-point interest-rate cut has helped revive their faith in the economy …
- Whatever happens, keep an eye on fresh data on GDP growth, inflation and jobless claims due to be released this week.
- These data could ultimately determine whether stocks hold on to their monthly gains, or give them up.
As volatility is on-call in today’s sector
- I am STILL wondering if … sentiment is moribund.
- Keep overall exposure low and be ready to exit quickly.
- As I have joked, “uncle algo and his electronic trading dwarfs” come to roost” until they fly away!
Also, the closer we come to the U.S. presidential election; volatility could inject by the VIX (fear gauge) stimulating risk.
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
